



Corp. Off.:- 201, "The Summit Business Bay"
Behind Guru Nanak Petrol Pump,
Off Andheri Kurla Road, Andheri (E),
Mumbai - 400 093 (India)
Ph. : +91 22 69073100

13th August 2026

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai-400051

Scrip Code: **533543**

Symbol: **BROOKS**

Sub: Outcome of Board Meeting held on Thursday, 13th August 2026.

Dear Sir/Madam,

Pursuant to provisions of Regulations 30 and 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their Meeting held today i.e., on Thursday, 13th August 2026 inter alia, considered, approved and taken on record the following:

1. Unaudited Financial Results along with the Limited Review Report thereon for the quarter ended on 30th June, 2026. Extract of the Unaudited Financial Results along with Limited Review Report is enclosed herewith.

The Board Meeting commenced at 4:00 P.M and concluded at 6:00 P.M.

The above information will also be available on the Company's website www.brookslabs.net.

We request you to kindly take the same on record.

Thanking You,

Yours faithfully,

For **BROOKS LABORATORIES LIMITED**

Krutika Rane

Company Secretary and Compliance Officer

Membership no: 66310

Encl.: As Stated

Independent Auditor's Limited Review Report on Unaudited Standalone Financial Results of Brooks Laboratories Limited for the quarter ended June 30, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Ind AS Financial Results of Brooks Laboratories Limited ('the Company') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation').
2. This Statement, which is the responsibility of the Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether standalone financial results are free of material misstatements. A review consists of making inquiries, primarily of people responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted



in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

5. As stated in Note 7 to the Statement of Unaudited Financial Results for the Quarter ended June 30, 2026, include the results of quarter ended March 31, 2026, being the balancing figures between the audited figures in respect of full financial year and the unaudited published figures up to nine months of the relevant financial year which were subject to limited reviewed by us.

Our opinion is not qualified on above mentioned matters.

For D M K H & Co

Chartered Accountants

Firm's Registration No. 116886W

ms Lokeshwar

CA Malavika Lokeshwar

Partner

Mem. No.: 108628

UDIN: 26108628QWMOPN7012

Place: Mumbai

Date: August 13, 2026



Independent Auditor's Limited Review Report on Unaudited Consolidated financial results of Brooks Laboratories Limited for the quarter ended on June 30, 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Brooks Laboratories Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Brooks Laboratories Limited ('the Holding Company') and its Jointly controlled entity for the quarter ended June 30, 2026 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of people responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Brooks Steriscience Limited	Jointly Controlled Entity



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

6. We did not review the financial results of the Jointly Controlled Entity vis Brooks Steriscience Limited included in the consolidated unaudited financial results, whose financial results include the Group's share of net loss of Rs. 320.55 Lakhs for the quarter ended June 30, 2026, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this Jointly controlled entity, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our opinion is not qualified on above mentioned matters.

For D M K H & Co

Chartered Accountants

Firm's Registration No. 116886W

ms Lokeshwar



CA Malavika Lokeshwar

Partner

Mem. No.: 108628

UDIN: 26108628FNYROA6505

Place: Mumbai

Date: August 13, 2026

Statements of Unaudited Financial Results for the quarter ended 30th June 2026

(Rs. In Lakhs)

Particulars	Standalone				Consolidated			
	Quarter Ended		Year Ended		Quarter Ended		Year Ended	
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
1 Income								
Revenue from operations	2,296.08	2,020.95	2,551.19	8,573.84	2,296.08	2,020.95	2,551.19	8,573.84
Other Income	17.67	43.83	21.70	117.05	17.67	43.83	21.70	117.05
Total income	2,313.75	2,064.78	2,572.89	8,690.89	2,313.75	2,064.78	2,572.89	8,690.89
2 Expenses								
(a) Cost of materials consumed	1,368.02	1,181.30	1,361.62	4,961.22	1,368.02	1,181.30	1,361.62	4,961.22
(b) Purchase of Stock in Trade	14.18	3.20	240.76	225.07	14.18	3.20	240.76	225.07
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(114.01)	57.39	(13.13)	(84.10)	(114.01)	57.39	(13.13)	(84.10)
(d) Employees benefits expenses	421.28	384.95	366.86	1,516.21	421.28	384.95	366.86	1,516.21
(e) Finance Costs	20.55	8.92	30.14	83.53	20.55	8.92	30.14	83.53
(f) Depreciation and amortization expenses	41.53	41.27	39.19	158.99	41.53	41.27	39.19	158.99
(g) Other expenses	420.34	326.32	282.39	1,249.47	420.34	326.32	282.39	1,249.47
Total Expenses	2,171.89	2,003.35	2,307.83	8,110.39	2,171.89	2,003.35	2,307.83	8,110.39
3 Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax	141.86	61.43	265.06	580.50	141.86	61.43	265.06	580.50
Share of Profit / (Loss) from Jointly controlled entities and associates	-	-	-	-	(320.55)	90.87	693.42	1,877.85
Profit/(Loss) before Exceptional item and tax	141.86	61.43	265.06	580.50	(178.69)	152.30	958.48	2,458.35
5 Exceptional items	-	-	-	-	-	-	-	-
6 Profit/(Loss) from ordinary activities before tax	141.86	61.43	265.06	580.50	(178.69)	152.30	958.48	2,458.35
7 Tax Expense:								
Deferred Tax Liability / (Assets)(Refer note 6)	-	-	-	-	-	-	-	-
MAT credit reversal	-	-	-	-	-	-	-	-
Tax of earlier years	-	-	-	-	-	-	-	-
8 Net Profit/(loss) after tax	141.86	61.43	265.06	580.50	(178.69)	152.30	958.48	2,458.35
9 Other Comprehensive Income								
Items That will not be reclassified into Profit or loss								
Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax)	-	(3.07)	-	(3.07)	-	(3.07)	-	(3.07)
10 Total Comprehensive income for the period	141.86	58.36	265.06	577.43	(178.69)	149.23	958.48	2,455.28
Net Profit attributable to								
Owners of equity	-	-	-	-	(178.69)	152.30	958.48	2,458.35
Non Controlling Interest	-	-	-	-	-	-	-	-
Other Comprehensive Income attributable to :								
Owners of equity	-	-	-	-	-	(3.07)	-	(3.07)
Non Controlling Interest	-	-	-	-	-	-	-	-
Total Comprehensive Income attributable to								
Owners of Equity	-	-	-	-	(178.69)	149.23	958.48	2,455.28
Non Controlling Interest	-	-	-	-	-	-	-	-
11 Paid-up equity share capital (Face Value of Rs. 10 each)	2,945.72	2,945.72	2,945.72	2,945.72	2,945.72	2,945.72	2,945.72	2,945.72
12 Reserves excluding Revaluation Reserves				9,138.68				9,319.99
13 Earnings per share (of Rs. 10/- each)								
(not annualized)								
(a) Basic	0.48	0.21	0.90	1.97	(0.61)	0.52	3.25	8.35
(b) Diluted	0.48	0.21	0.90	1.97	(0.61)	0.52	3.25	8.35

Notes:

- The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on August 13, 2026
- The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016
- Brooks Steriscience Limited, a jointly controlled entity, recorded revenue from operations of Rs. 1,751.30 lakhs for the quarter ended 30 June 2026, resulting in a loss after tax of Rs. 654.18 lakhs. Accordingly, the Company's share of the loss after tax of the jointly controlled entity for the quarter ended 30 June 2026 amounting to Rs. 320.55 lakhs has been recognised and reported above.
- The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures".
- In the absence of reasonable certainty of future taxable profit, The Holding Company has not recognized deferred tax asset on its business losses/depreciation in accordance with Ind As 12 "Income taxes".
- The Company operates through two reportable business segments in accordance with Ind AS 108 – Operating Segments, namely Trading and Manufacturing. Trading comprises principal-to-principal trading activities, while Manufacturing includes the Company's own manufacturing operations and loan-licensing business.
- The numbers for quarter ended March 31, 2026 are the balancing numbers between audited numbers in respect of the full financial year ended March 31, 2026 and the published reviewed year to date numbers upto and for the nine months period ended December 31, 2025
- Prior period figures have been regrouped and reclassified where necessary.



Place : Baddi
Date : 13/08/2026

For and on behalf of the Board

Bhushan Singh Rana
Bhushan Singh Rana
Din : 10289384
Whole time Director



Brooks Laboratories Limited

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net

Segment-wise Revenue, Results, Assets and Liabilities

(Rs. In Lakhs)

Particulars	Standalone				Consolidated			
	Quarter Ended		Year Ended		Quarter Ended		Year Ended	
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
1 Segment Revenue								
a) Trading	18.53	23.22	36.19	286.58	18.53	23.22	36.19	286.58
b) Manufacturing	2,277.55	1,997.73	2,515.00	8,287.26	2,277.55	1,997.73	2,515.00	8,287.26
	2,296.08	2,020.95	2,551.19	8,573.84	2,296.08	2,020.95	2,551.19	8,573.84
Less: Inter segment Revenue	-	-	-	-	-	-	-	-
	2,296.08	2,020.95	2,551.19	8,573.84	2,296.08	2,020.95	2,551.19	8,573.84
Add: Unallocated	-	-	-	-	-	-	-	-
Total revenue from operations	2,296.08	2,020.95	2,551.19	8,573.84	2,296.08	2,020.95	2,551.19	8,573.84
2 Segment Results								
(a) Trading	(13.79)	(11.68)	(14.18)	(6.38)	(13.79)	(11.68)	(14.18)	(6.38)
(b) Manufacturing	185.10	88.15	312.59	694.26	185.10	88.15	312.59	694.26
Total Segment results	171.31	76.47	298.41	687.88	171.31	76.47	298.41	687.88
Less:								
(i) Finance costs	20.55	8.92	30.14	83.53	20.55	8.92	30.14	83.53
(ii) Other un-allocable (income) net of un-allocable expenditure	8.90	6.12	3.21	23.85	8.90	6.12	3.21	23.85
Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax	141.86	61.43	265.06	580.50	141.86	61.43	265.06	580.50
Share of Profit / (Loss) from Jointly controlled entities and associates	-	-	-	-	(320.55)	90.87	693.42	1,877.85
Profit/(Loss) before Exceptional item and tax	141.86	61.43	265.06	580.50	(178.69)	152.30	958.48	2,458.35
3 Segment Assets								
(a) Trading	5,001.46	5,025.89	5,041.91	5,025.89	4,925.22	5,125.16	4,490.75	5,125.16
(b) Manufacturing	9,791.81	8,855.30	9,635.68	8,855.30	9,728.80	8,937.34	9,180.17	8,937.34
Total segment assets	14,793.27	13,881.19	14,677.59	13,881.19	14,654.02	14,062.50	13,670.92	14,062.50
Add: Unallocated	-	754.89	8.52	754.89	-	754.89	8.52	754.89
Total assets	14,793.27	14,636.08	14,686.11	14,636.08	14,654.02	14,817.39	13,679.44	14,817.39
4 Segment Liabilities								
(a) Trading	55.66	70.70	94.51	70.70	55.66	70.70	94.51	70.70
(b) Manufacturing	2,511.33	2,480.98	2,820.02	2,480.98	2,511.33	2,480.98	2,820.02	2,480.98
Total segment liabilities	2,566.99	2,551.68	2,914.53	2,551.68	2,566.99	2,551.68	2,914.53	2,551.68
Add: Unallocated	-	-	-	-	-	-	-	-
Total liabilities	2,566.99	2,551.68	2,914.53	2,551.68	2,566.99	2,551.68	2,914.53	2,551.68

Place : Baddi
Date : 13/08/2026

For and on Behalf of Board

Bhushan Singh Rana
Din : 10289384
Whole time Director